Histopathology Following CCH Injection

Completed · Phase 2

Conditions studied: Characteristics of Subcutaneous Tissue

In brief

To evaluate the histopathology of subcutaneous tissue isolated after single or multiple Collagenase Clostridium Histolyticum (CCH) injection techniques in adult female participants undergoing abdominoplasty.

Key facts

Study ID

NCT04236635

Run by

Endo USA Inc., a Keenova Therapeutics Company

People needed

10

Starts

2019-12-20

Expected to finish

2020-10-26

Last updated by the study team

2022-04-12

Who can join

Age: 18 and older, up to 55. Sex: female. Healthy volunteers: accepted.

You may qualify if…

• Be adequately informed and understand the nature and risks of the study and be able to provide consent.
• Be undergoing planned elective abdominoplasty.
• Be willing to have their tissue donated for evaluation.
• Be judged to be in good health.
• Have a negative pregnancy test.
• Be willing and able to cooperate with the requirements of the study.

You may not qualify if…

• Is from a vulnerable population, as defined by the US Code of Federal Regulations (CFR) Title 45, Part 46, Section 46.111(b) and other local and national regulations, including but not limited to, employees (temporary, part-time, full time, etc) or a family member of the research staff conducting the study, or of the sponsor, or of the contract research organization, or of the Institutional Review Board (IRB)/Independent Ethics Committee (IEC).
• Has systemic conditions (coagulation disorders, malignancy, keloidal scar, abnormal wound healing) that restricts study participation.
• Has local (in the areas to be treated) conditions (thrombosis, vascular disorder, active infection/inflammation, active cutaneous alteration, tattoo/mole) that restricts study participation.
• Required use of anticoagulant or antiplatelet medication (except ≤ 150 mg aspirin daily) before or during participation in the trial.
• Past history of any abdominal surgery, including but not limited to: liposuction, caesarean section, appendectomy, cholecystectomy, or umbilical hernia repair.
• Has used or intends to use any local applications/therapies/injections/procedures that restricts study participation.
• Is presently nursing or providing breast milk in any manner.
• Intends to become pregnant during the study.
• Intends to initiate an intensive sport or exercise program regimen during the study.
• Intends to use any tanning spray or tanning booths during the study.
• Has received any investigational drug or treatment within 30 days prior to first injection of study drug.
• Has a known systemic allergy to collagenase or any other excipient of study drug.
• Has received any collagenase treatment at any time prior to treatment in this study.
• Any other condition(s) that, in the investigator's opinion, might indicate the subject to be unsuitable for the study.

Where it is running

• Endo Clinical Trial Site #1 — Montclair, New Jersey, United States
• Endo Clinical Trial Site #2 — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.